Provectus Biopharmaceuticals Inc (PVCT)

[waveduke]

Child’s Illness Steers a CFO’s Career

I do not know the nuances of this company, but interesting article on the CFO:

http://ww2.cfo.com/people/2014/05/childs-illness-steers-cfos-career/view-all/ (full article)

His daughter's cancer led to a job with a drug-maker that, after 10 years of intense capital formation, is now listed on the NYSE.
David McCann

Peter Culpepper: fighting the good fight.

Culpepper, 54, has been in charge of finance for 10 years at Provectus Biopharmaceuticals, a cancer-drug maker. Its most developed product, PV-10, is an injectable treatment for advanced cutaneous melanoma. It’s just wound up Phase-2 clinical trials, where it was used effectively among test groups. The company has applied for a “breakthrough therapy” designation for PV-10, which would accelerate the approval process, and also is working on treatments for other forms of melanoma as well as liver and breast cancer.

It was in 1999, when Culpepper was controller at Metromedia International Telecommunications, that cancer, suddenly and sadly, became his passion. His oldest child, Victoria, 5 at the time, was hospitalized for what was initially thought to be an epileptic seizure. The actual diagnosis was far more sobering: brain cancer.

Most of the tumor was surgically removed, leaving the family to evaluate treatment options. It was agonizing. Culpepper and his wife consulted with medical professionals at all of the top cancer hospitals in the greater New York area, where they were living at the time, and didn’t like what they heard. “They were calling for two years of chemotherapy and full-body radiation, just horrific amounts of chemo and radiation,” he says. “We just felt helpless.”